In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

The company said the Virginia facility "would be AstraZeneca’s largest single manufacturing investment in the world." The ...

Revenue from oncology products made up 43 per cent of Astrazeneca's revenue in the first half of 2025, up 15 per cent year on ...

Drugmaker Astrazeneca said on Tuesday that "strong growth momentum" had continued in H1, with "excellent R&D pipeline ...

Pharmaceutical giant AstraZeneca has reported increased revenue across all its major geographic regions and increased interim profits as the listed business maintained its growth ...

The pharmaceutical giant said second-quarter revenue increased to $14.46 billion from $12.94 billion. U.S. revenue was up 13% ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...

AstraZeneca, a pharmaceutical company, has announced its plans to bring a drug substance manufacturing facility to Virginia.

The FTSE 100 has started higher, up 13 points to 9,094 in a mixed early trading for European markets. Games Workshop Group ...

AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to go somewhere in Virginia.

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...